Stay updated on DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the number of patients enrolled in a phase Ib/II trial studying the effectiveness of dendritic cell therapy after cryosurgery in combination with pembrolizumab for treating patients with stage III-IV melanoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:34.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of what eligibility criteria entail for clinical research participation.
    Difference
    41%
    Check dated 2024-05-22T21:01:30.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:16:06.000Z thumbnail image

Stay in the know with updates to DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page.